---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-22-000147"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:03:22.055137+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Salarius Pharma reports Q3 net loss $14.4M; seclidemstat trial paused on safety, FDA partial hold

## Summary
- Q3 2022 net loss $14.4M ($6.41/diluted share) vs $3.7M ($2.09) in Q3 2021; includes $8.9M goodwill impairment.
- Cash and equivalents $16.8M at Sep 30, 2022, down from $29.2M at Dec 31, 2021; cash runway into H2 2023.
- Seclidemstat sarcoma trial on partial clinical hold after SUSAR; enrollment paused in both company and MD Anderson studies.
- SP-3164 IND on track for H1 2023; favorable preclinical data presented at ASH abstract.
- Nine-month net loss $25.2M ($12.13/share) vs $8.7M ($5.41) in prior period; operating cash burn $12.9M.

## SEC filing metadata
- accession: 0001615219-22-000147
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/0001615219-22-000147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/flks-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-22-000147
- JSON: https://secwatch.observer/filing/0001615219-22-000147.json
- Plain text: https://secwatch.observer/filing/0001615219-22-000147.txt

## Key facts
- Earnings Releases
  Decoy Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share, EPS $6.41 per share.
  - Period: three and nine months ended September 30, 2022
  - Net income: Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share
  - EPS: $6.41 per share
  - Result: reported results
  source text: Salarius Pharmaceuticals, Inc. (the “Company”) reported financial results for the three and nine months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/0001615219-22-000147-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.